ArticleNeurosurgery2019
BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.
Article in Neurosurgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 5 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases.Frontiers in oncology · 2022Pooled it
- Impact of Previous Local Treatment for Brain Metastases on Response to Molecular Targeted Therapy in BRAF-Mutant Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) in brain metastases: a systematic review.Cancer metastasis reviews · 2021Pooled it
- The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review.International journal of cancer · 2020Pooled it
- Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies - a comprehensive review.Frontiers in oncology · 2026Review
- Pyrotinib combining with radiotherapy on breast cancer with brain metastasis.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies.Frontiers in oncology · 2022Review
- Management Strategies for Large Brain Metastases.Frontiers in oncology · 2022Review
- Review
- Long-term control of melanoma brain metastases with co-occurring intracranial infection and involuntary drug reduction during COVID-19 pandemic: A case report.World journal of clinical cases · 2021Article
- Management of brain metastases according to molecular subtypes.Nature reviews. Neurology · 2020Review
- Review
- Oligometastasis and local ablation in the era of systemic targeted and immunotherapy.Radiation oncology (London, England) · 2020Review
- Current Treatment of Melanoma Brain Metastasis.Current treatment options in oncology · 2020Review
- Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.Neuro-oncology · 2020Review
- Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases.Frontiers in oncology · 2020Review
- Concurrent Radiosurgery and Systemic Therapies for Melanoma Brain Metastases: A Systematic Review.Cureus · 2019Review
- Radiotherapy for Melanoma: More than DNA Damage.Dermatology research and practice · 2019Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundThe BRAF mutation has been identified as a potent target for the treatment of metastatic melanoma and BRAF inhibitors (BRAFi) have demonstrated promising results against melanoma brain metastases (BM).
objectiveTo further investigate the effectiveness of this combined treatment regimen.
methodsIn this multicenter retrospective cohort study, 198 patients with known BRAF mutation status and treated with stereotactic radiosurgery (SRS) between 2011 and 2015 were identified. Kaplan-Meier methodology and multivariate regression analysis was then used to compare survival based on each parameter.
resultsThe median survival after the diagnosis of BM in patients with BRAF mutation who received BRAFi was increased compared to survival in patients with wild-type BRAF (BRAF wt). In multivariate analysis, the BRAF mutation was an independent, positive prognostic factor with a hazard ratio of 0.59. BRAF mutated Patients who received BRAFi following SRS had improved survival compared to patients who received it before (P < .001) or concurrently (P = .007). PD-1 inhibitors improved survival, with more pronounced effect in patients not carrying the BRAF mutation. Among the patients who were treated with BRAFi, 10.4% developed intracerebral hematoma (ICH), in comparison to 3% of patients who were not treated with BRAFi (P = .03).
conclusionIn the setting of widespread use of BRAFi, the presence of a BRAF mutation is an independent predictor of better prognosis in patients with melanoma BM that underwent SRS. The effect of BRAFi is optimal when treatment is initiated at least 1 wk following SRS. BRAFi may increase the frequency of asymptomatic ICH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.